Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14324475 | 0.90 | CYP3A4 (0.44) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2404008 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2401915 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL14764310 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2405050 | 0.88 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2403910 | 0.88 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2401937 | 0.88 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL2402810 | 0.86 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL2403086 | 0.86 | CYP2C9 (0.46) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C | |
| SCHEMBL14764258 | 0.85 | PTGES2 (0.45) | CYP3A4CYP2C9CYP2C19KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542545-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. | 2012-12-27 | — | — | US | disclosed |
| WO-2011106992-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | HCCS, EIF2AK2, RNGTT | CYP3A4 977/4885CYP2C9 819/4885CYP2C19 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.